Switch theme
Sign up to access all valuation multiples
Chabiotech Co Ltd is engaged in the manufacturing of biological products.
2002
n/a
Last FY Revenue $760M
Last FY EBITDA $55.2M
$861M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Chabiotech achieved revenue of $760M and an EBITDA of $55.2M.
Chabiotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chabiotech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $760M | XXX | XXX | XXX |
| Gross Profit | XXX | $200M | XXX | XXX | XXX |
| Gross Margin | XXX | 26% | XXX | XXX | XXX |
| EBITDA | XXX | $55.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 7% | XXX | XXX | XXX |
| EBIT | XXX | -$43.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -6% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.9M | XXX | XXX | XXX |
| Net Margin | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | $376M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chabiotech's stock price is KRW 10410 (or $8).
Chabiotech has current market cap of KRW 635B (or $462M), and EV of KRW 1.18T (or $861M).
See Chabiotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $861M | $462M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chabiotech has market cap of $462M and EV of $861M.
Chabiotech's trades at 1.1x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Chabiotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chabiotech's P/E ratio is not available.
See valuation multiples for Chabiotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $462M | XXX | $462M | XXX | XXX | XXX |
| EV (current) | $861M | XXX | $861M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -19.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -78.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChabiotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Chabiotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chabiotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chabiotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chabiotech acquired XXX companies to date.
Last acquisition by Chabiotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Chabiotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chabiotech founded? | Chabiotech was founded in 2002. |
| Where is Chabiotech headquartered? | Chabiotech is headquartered in South Korea. |
| Who is the CEO of Chabiotech? | Chabiotech's CEO is Mr. Sang-Hoon Oh. |
| Is Chabiotech publicy listed? | Yes, Chabiotech is a public company listed on KRX. |
| What is the stock symbol of Chabiotech? | Chabiotech trades under 085660 ticker. |
| When did Chabiotech go public? | Chabiotech went public in 2005. |
| Who are competitors of Chabiotech? | Similar companies to Chabiotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Chabiotech? | Chabiotech's current market cap is $462M |
| Is Chabiotech profitable? | Yes, Chabiotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
